Opinion|Videos|July 23, 2026 (Updated: July 23, 2026)
Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care
Alireza Atri introduces mild behavioral impairment as an early-emerging framework for behavioral changes preceding formal dementia diagnosis.
Advertisement
Episodes in this series
Alireza Atri introduces mild behavioral impairment as an early-emerging framework for behavioral changes preceding formal dementia diagnosis. Panel outlines multifactorial triggers: medical (UTIs, pain, constipation, medication side effects, delirium) and psychosocial/environmental (overstimulation, unmet needs, caregiver communication). ~90% of AD patients managed by primary care/NPs/PAs — empowering these clinicians for early recognition is critical.
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
5